AtaiBeckley (ATAI) Non-Current Debt (2022 - 2025)

AtaiBeckley (ATAI) posted quarterly Non-Current Debt of $14.1 million for Q4 2024.

AtaiBeckley (ATAI) Non-Current Debt (2022 - 2025) Analysis & Trends

AtaiBeckley's Non-Current Debt history runs 1 years deep, the most recent figure standing at $14.1 million for Q4 2024.

Quarterly Non-Current Debt fell 38.57% year-over-year to $9.3 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $9.3 million (down 38.57% YoY) and the FY2024 annual result came in at $20.5 million, up 36.29% from the prior year.
Non-Current Debt slipped to $9.3 million in Q1 2025 per ATAI's latest filing, from $20.5 million in the prior quarter.
Over five years, Non-Current Debt peaked at $20.5 million in Q4 2024 and troughed at $9.3 million in Q1 2025.
A 4-year average of $15.4 million and a median of $15.0 million in 2023 frame the typical range for Non-Current Debt.
The sharpest annual moves came in 2024 and 2025: Non-Current Debt surged 36.29% in 2024, then sank 38.57% in 2025.
Over 4 years, Non-Current Debt stood at $14.7 million in 2022, then gained by 2.35% to $15.0 million in 2023, then soared by 36.29% to $20.5 million in 2024, then plunged by 54.65% to $9.3 million in 2025.
According to Business Quant data, Non-Current Debt over the past three periods registered $9.3 million, $20.5 million, and $20.3 million for Q1 2025, Q4 2024, and Q3 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	882.16 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	8.96 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	546.77 Mn
10	AtaiBeckley	2.69 Bn	2.69 Bn	-	-

Download Data